Sanofi-Aventis to complete Zentiva acquisition
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis will hold a 94% stake in the Czech Republic's Zentiva when it completes its acquisition on March 11th. All the conditions put out by Sanofi-Aventis Europe, a subsidiary which is handling the deal, have been successfully fulfilled, it added.
You may also be interested in...
Sanofi Finalizes Zentiva Sale With Focus Back On Turnaround
A share purchase agreement for the sale of Zentiva has been signed with private equity group Advent, so Sanofi can concentrate on making the most of its new acquisitions.
Poland's new law fixes prices and trade mark-ups of reimbursed drugs
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
Global pharma boosts business in Russia - Why Russia (introduction)
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.